Intermountain Healthcare Inks Taiwanese Distribution Deal for NGS Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – US provider Intermountain Healthcare has signed a distribution deal allowing Taiwan's Prisma Biotech to sell the ICG100 tumor sequencing test in that country.

The next-generation sequencing-based ICG100 test provides analyzes 100 genes for patient-specific mutations that could suggest personalized drug treatments. Intermountain controls the rights to the next-generation sequencing-based test through a contract with Prisma's fully-owned subsidiary, ReadGene.

Financial and other details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Apr
11
Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.